In 1967, Allergan acquired a 24-acre industrial site from the Irvine Company and built a new 100,000-square ... In 2020, it was acquired by AbbVie, which has been a good parent by investing in ...

While very early, the results are encouraging, according to Ray Wang, a specialist in metabolic disorders at the University of California, Irvine ... licensing deal with AbbVie for an AAV8 ...

It's encouraging to see that AbbVie has been growing its earnings per share at 5.7% a year over the past five years. While EPS is growing at a decent rate, but future growth could be limited by ...

In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer ...

AbbVie, with a market cap of over $300 billion, shows strong cash flow potential despite patent expirations, making it a valuable investment. The company reported strong 3Q financials, with ...

AbbVie will write off $3.5 billion related to its $8.7 billion investment in Cerevel Therapeutics following the failure of the company's key schizophrenia drug, emraclidine, The Wall Street ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

AbbVie will take an impairment charge of approximately $3.5 billion related to the back-to-back failures of its pricey drug candidate emraclidine in two mid-stage schizophrenia trials, the pharma ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...